← Leaderboards
Christiane Querfeld
Beckman Research Institute/City Of Hope
$3,066,660
Attributed
$3,308,061
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $830.5K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,308,061 · 2
By mechanism
R01$2,825,258 · 1
R21$482,803 · 1
Top collaborators
- Joo Song2 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Behnam Badie$11,237,051
- Christine Brown$5,264,024
- Jianhua Yu$11,234,533
- Joo Song$608,042
- Jeffrey Y Wong$4,970,582
Others in their field
Other Emerging Leaders on “Lymphoma”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,138,591
- Leonard Freedman · Leidos Biomedical Research, Inc.$10,332,151
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,187,946
- Javeed Iqbal · University Of Nebraska Medical Center$5,566,166
- John Karijolich · Vanderbilt University Medical Center$5,446,739
Research focus
LymphomaFutureMolecularTumorPathway InteractionsGeneticMolecular ProfilingSiteResearch PersonnelSkinSamplingPatternLeadGenetic TranscriptionCellsCd8-Positive T-LymphocytesAntitumor ResponseCd28 GeneAffectComplexEnvironmentDendritic CellsAnti-Pd-L1Clinically Relevant
Grant awards (7)
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy$552,383
R01 · FY2023 · CA · contact PI
Genomic Analysis of Cutaneous CD30+ Lymphoproliferative Disorders$215,936
R21 · FY2023 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy$563,656
R01 · FY2022 · CA · contact PI
Genomic Analysis of Cutaneous CD30+ Lymphoproliferative Disorders$266,867
R21 · FY2022 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy$563,656
R01 · FY2021 · CA · contact PI
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy$568,426
R01 · FY2020 · CA · contact PI
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy$577,137
R01 · FY2019 · CA · contact PI